VNVC invited a leading global corporation to design a VND 2,000 billion (~81.3 million USD) vaccine manufacturing plant

VNVC Vaccine and Biopharmaceutical Manufacturing Plant has a total investment of nearly 80 million USD (approximately VND 2,000 billion), designed and constructed by Rieckermann Group (Germany) using world-class advanced technology, incorporating the Net Zero goal to reduce greenhouse gas emissions to zero.

At the beginning of 2025, Vietnam Vaccine Joint Stock Company (VNVC) officially signed a contract with Rieckermann Group (Germany) for the design of the VNVC Vaccine and Biopharmaceutical Manufacturing Plant. Rieckermann is a leading global designer in the field of vaccine and pharmaceutical manufacturing facilities.

Rieckermann Group (Germany) is a globally renowned corporation with over 130 years of experience in designing pharmaceutical, vaccine, and biopharmaceutical manufacturing plants worldwide. The company has designed numerous manufacturing facilities for leading global pharmaceutical and vaccine corporations such as GSK, MSD, and Roche, adhering to the highest standards of pharmaceutical manufacturing, including GMP regulations set by the EU, FDA, PIC/S, and WHO.

To meet VNVC's stringent requirements, Rieckermann has optimally utilized over 26,000 square meters to design a modern, integrated manufacturing complex. This facility includes vaccine and biopharmaceutical production areas, an animal research and breeding building, and various other utility zones, all designed to fully comply with the highest global standards.

The vaccine and biopharmaceutical manufacturing facility must meet the highest GMP standards set by the EU, FDA, PIC/S, and WHO. Additionally, the specialized building for housing laboratory animals will be designed to conduct preclinical and clinical trials for vaccines and biopharmaceuticals in compliance with international GLP (Good Laboratory Practice) standards and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) certification. These are top-tier standards that ensure both regulatory compliance and the ethical treatment of laboratory animals, which are critical in this field.

Notably, the entire facility is designed according to LEED (Leadership in Energy & Environmental Design) standards, a rigorous international certification for comprehensive green building construction. This ensures environmental protection, energy efficiency, and alignment with the global Net Zero trend, aiming for zero net greenhouse gas emissions. This will be Vietnam’s first vaccine manufacturing plant to meet this standard, contributing to the country’s goal of achieving net-zero emissions by 2050.

Once operational, the VNVC manufacturing plant will be the first vaccine facility in Vietnam to fully comply with global standards for both technology and environmental sustainability. This project marks a significant milestone in the sustainable development strategy for Vietnam’s vaccine industry, paving the way for the country to achieve vaccine self-sufficiency, ensuring health security, and enhancing the global competitiveness of Vietnam’s pharmaceutical sector.

Speaking at the signing ceremony, Mr. Jorge Domingo Guerra, Business Development Director of Rieckermann Group, stated that the VNVC Vaccine and Biopharmaceutical Manufacturing Plant project not only demonstrates Vietnam’s remarkable progress in enhancing biopharmaceutical infrastructure but also represents a significant step forward in addressing global health challenges.

Mr. Jorge Domingo Guerra affirmed Rieckermann's commitment to delivering an innovative, world-class design for VNVC, fully meeting international standards and criteria for safety, efficiency, and long-term sustainability. He emphasized that the facility would ensure the continuous production of essential vaccines and biopharmaceutical products using cutting-edge global technologies.

"By leveraging our expertise and experience in engineering solutions, we are confident that VNVC’s vaccine manufacturing plant will become a cornerstone of Vietnam’s efforts to ensure a stable supply of essential vaccines and biopharmaceuticals for both the domestic and global population. This collaboration is not just about building a facility - it is about laying the foundation for a healthier and more sustainable future", shared Mr. Jorge Domingo Guerra in his remarks.

VNVC Vaccine and Biopharmaceutical Manufacturing Plant will be one of the first facilities in Southeast Asia to make a significant investment in state-of-the-art production lines, including vial filling, syringe, and injection pen technology. Notably, the plant will feature isolator-based filling and packaging lines for vials, syringes, and injection pens - a cutting-edge aseptic manufacturing technology used globally. As of now, VNVC is the first in Vietnam to implement this advanced technology.

Once operational, VNVC manufacturing plant is expected to collaborate with leading global vaccine manufacturers, gradually participating in various stages of vaccine and biopharmaceutical production. The ultimate goal is to acquire technology transfer and achieve independent vaccine production in the future.

Earlier, in October 2024, VNVC initiated a collaboration agreement aimed at technology transfer and the production of various vaccines from Sanofi (France), a leading global pharmaceutical company. These include influenza vaccines and the 6-in-1 vaccine, which will be manufactured at VNVC's facility. This initiative will help Vietnam secure a stable supply of high-quality vaccines for both children and adults, reducing reliance on imported vaccines.

In addition to vaccine production, VNVC manufacturing complex is also equipped with state-of-the-art infrastructure to support scientific research and clinical trials for vaccines. This will create favorable conditions to attract leading experts from Vietnam and around the world to collaborate and work at the facility.

Alongside the launch of VNVC Vaccine and Biopharmaceutical Manufacturing Plant, the Tam Anh General Hospital System plans to break ground on Tam Anh University by the end of 2025. This initiative aims to enhance education, healthcare, preventive medicine, and the production of high-quality vaccines and biopharmaceuticals, contributing to the overall improvement of public health and quality of life for the Vietnamese people.

OTHER ARTICLES